Skip to main content

Advertisement

SpringerLink
Log in

Does Proton Therapy Have a Future in CNS Tumors?

  • Neuro-oncology (R Soffietti, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Proton therapy is characterized by certain physical properties leading to a reduction in integral dose. As proton therapy becomes more widely available, the ongoing discussion on the real indications for proton therapy becomes more important. In the present article, data on proton therapy for tumors of the central nervous system (CNS) is summarized and discussed in view of modern photon treatments. Still today, no randomized controlled trials are available confirming any clinical benefit of protons in CNS tumors. For certain skull base lesions, such as chordomas and chondrosarcomas, dose escalation is possible with protons thus patients should be referred to a proton center if readily available. For vestibular schwannoma, at present, proton data are inferior to advanced photons. For glioma patients, early data is present for low-grade gliomas, presenting comparable results to photons; dose escalation studies for high-grade gliomas have led to significant side effects, thus strategies of dose-escalation need to rethought. For skull base meningiomas, data from stereotactic series and IMRT present excellent local control with minimal side effects, thus any improvement with protons might only be marginal. The largest benefit is considered in pediatric CNS tumors, due to the intricate radiation sensitivity of children’s normal tissue, as well as the potential of long-term survivorship. Long-term data is still lacking, and even recent analyses do not all lead to a clear reduction in side effects with improvement of outcome; furthermore, clinical data seem to be comparable. However, based on the preclinical evidence, proton therapy should be evaluated in every pediatric patient. Protons most likely have a benefit in terms of reduction of long-term side effects, such as neurocognitive sequelae or secondary malignancies; moreover, dose escalation can be performed in radio-resistant histologies. Clinical data with long-term follow-up is still warranted to prove any superiority to advanced photons in CNS tumors. If available, protons should be evaluated for chordoma or chondrosarcoma of the skull base and pediatric tumors. However, many factors are important for excellent oncology care, and no time delay or inferior oncological care should be accepted for the sake of protons only.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as • Of importance

  1. Combs SE, Schulz-Ertner D, Herfarth KK, Krempien R, Debus J. Advances in radio-oncology. From precision radiotherapy with photons to ion therapy with protons and carbon ions. Chirurg. 2006;77:1126–32.

    Article  CAS  PubMed  Google Scholar 

  2. Combs SE, Adeberg S, Dittmar JO, Welzel T, Rieken S, Habermehl D, et al. Skull base meningiomas: long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol. 2013;106:186–91.

    Article  PubMed  Google Scholar 

  3. Combs SE, Behnisch W, Kulozik AE, Huber PE, Debus J, Schulz-Ertner D. Intensity modulated radiotherapy (IMRT) and fractionated stereotactic radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer. 2007;7:177.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Straube C, Pigorsch SU, Scherb H, Wilkens JJ, Bier H, Combs SE. Reduced volume SIB-IMRT/IGRT to head and neck cancer in elderly and frail patients: outcome and toxicity. Radiat Oncol. 2016;11:133.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Combs SE, Volk S, Schulz-Ertner D, Huber PE, Thilmann C, Debus J. Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys. 2005;63:75–81.

    Article  PubMed  Google Scholar 

  6. Harrabi SB, Adeberg S, Welzel T, Rieken S, Habermehl D, Debus J, et al. Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects. Radiat Oncol. 2014;9:203.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Specht HM, Kessel KA, Oechsner M, Meyer B, Zimmer C, Combs SE. HFSRT of the resection cavity in patients with brain metastases. Strahlenther Onkol. 2016;192:368–76.

    Article  PubMed  Google Scholar 

  8. Combs SE, Welzel T, Kessel K, Habermehl D, Rieken S, Schramm O, et al. Hearing preservation after radiotherapy for vestibular schwannomas is comparable to hearing deterioration in healthy adults and is accompanied by local tumor control and a highly preserved quality of life (QOL) as patients’ self-reported outcome. Radiother Oncol. 2013;106:175–80.

    Article  PubMed  Google Scholar 

  9. Combs SE, Welzel T, Schulz-Ertner D, Huber PE, Debus J. Differences in clinical results after LINAC-based single-dose radiosurgery versus fractionated stereotactic radiotherapy for patients with vestibular schwannomas. Int J Radiat Oncol Biol Phys. 2010;76:193–200.

    Article  PubMed  Google Scholar 

  10. Castro JR, Saunders WM, Tobias CA, Chen GT, Curtis S, Lyman JT, et al. Treatment of cancer with heavy charged particles. Int J Radiat Oncol Biol Phys. 1982;8:2191–8.

    Article  CAS  PubMed  Google Scholar 

  11. Munzenrider JE. Recent advances in radiotherapy. Rev Interam Radiol. 1977;2:123–33.

    CAS  PubMed  Google Scholar 

  12. Habrand JL, Schlienger P, Schwartz L, Pontvert D, Lenir-Cohen-Solal C, Helfre S, et al. Clinical applications of proton therapy. Experiences and ongoing studies. Radiat Environ Biophys. 1995;34:41–4.

    Article  CAS  PubMed  Google Scholar 

  13. Combs SE, Debus J. Treatment with heavy charged particles: systematic review of clinical data and current clinical (comparative) trials. Acta Oncol. 2013;52:1272–86.

    Article  PubMed  Google Scholar 

  14. Tsujii H. History and current status of charged particle therapy in Japan. Igaku Butsuri. 2012;32:98–103.

    PubMed  Google Scholar 

  15. Paganetti H, van Luijk P. Biological considerations when comparing proton therapy with photon therapy. Semin Radiat Oncol. 2013;23:77–87.

    Article  PubMed  Google Scholar 

  16. Combs SE, Kessel K, Habermehl D, Haberer T, Jakel O, Debus J. Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta Oncol. 2013;52:1504–9.

    Article  PubMed  Google Scholar 

  17. Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 2012;42:670–85.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Combs SE, Bruckner T, Mizoe JE, Kamada T, Tsujii H, Kieser M, et al. Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. Radiother Oncol. 2013;108:132–5.

    Article  CAS  PubMed  Google Scholar 

  19. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ, Jr. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N. Engl. J. Med. 2016;374:1344–55

  20. Hauswald H, Rieken S, Ecker S, Kessel KA, Herfarth K, Debus J, et al. First experiences in treatment of low-grade glioma grade I and II with proton therapy. Radiat Oncol. 2012;7:189.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Wilkinson B, Morgan H, Gondi V, Larson GL, Hartsell WF, Laramore GE, et al. Low levels of acute toxicity associated with proton therapy for low-grade glioma: a Proton Collaborative Group study. Int J Radiat Oncol Biol Phys. 2016;96:E135.

    Article  CAS  PubMed  Google Scholar 

  22. Sherman JC, Colvin MK, Mancuso SM, Batchelor TT, Oh KS, Loeffler JS, et al. Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neuro-Oncol. 2016;126:157–64.

    Article  CAS  Google Scholar 

  23. Shih HA, Sherman JC, Nachtigall LB, Colvin MK, Fullerton BC, Daartz J, et al. Proton therapy for low-grade gliomas: results from a prospective trial. Cancer. 2015;121:1712–9.

    Article  PubMed  Google Scholar 

  24. Fitzek MM, Thornton AF, Rabinov JD, Lev MH, Pardo FS, Munzenrider JE, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg. 1999;91:251–60.

    Article  CAS  PubMed  Google Scholar 

  25. Fitzek MM, Thornton AF, Harsh G, Rabinov JD, Munzenrider JE, Lev M, et al. Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial. Int J Radiat Oncol Biol Phys. 2001;51:131–7.

    Article  CAS  PubMed  Google Scholar 

  26. Hamm K, Henzel M, Gross MW, Surber G, Kleinert G, Engenhart-Cabillic R. Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base meningiomas. Zentralbl Neurochir. 2008;69:14–21.

    Article  CAS  PubMed  Google Scholar 

  27. Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R. Stereotactic radiotherapy of benign meningioma in the elderly: clinical outcome and toxicity in 121 patients. Radiother Oncol. 2014;111:457–62.

    Article  PubMed  Google Scholar 

  28. Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R. Stereotactic radiation therapy for benign meningioma: long-term outcome in 318 patients. Int J Radiat Oncol Biol Phys. 2014;89:569–75.

    Article  PubMed  Google Scholar 

  29. Minniti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol. 2009;4:42.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Minniti G, Clarke E, Cavallo L, Osti MF, Esposito V, Cantore G, et al. Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas. Radiat Oncol. 2011;6:36.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Fossati P, Vavassori A, Deantonio L, Ferrara E, Krengli M, Orecchia R. Review of photon and proton radiotherapy for skull base tumours. Rep Pract Oncol Radiother. 2016;21:336–55.

    Article  PubMed  Google Scholar 

  32. Mozes P, Dittmar JO, Habermehl D, Tonndorf-Martini E, Hideghety K, Dittmar A, Debus J, Combs SE. Volumetric response of intracranial meningioma after photon or particle irradiation. Acta Oncol. 2016;1–7. doi:10.1080/0284186X.2016.1259659

  33. Wenkel E, Thornton AF, Finkelstein D, Adams J, Lyons S, De La MS, et al. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:1363–70.

    Article  CAS  PubMed  Google Scholar 

  34. Vernimmen FJ, Harris JK, Wilson JA, Melvill R, Smit BJ, Slabbert JP. Stereotactic proton beam therapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2001;49:99–105.

    Article  CAS  PubMed  Google Scholar 

  35. Noel G, Bollet MA, Calugaru V, Feuvret L, Haie-Meder C, Dhermain F, et al. Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. Int J Radiat Oncol Biol Phys. 2005;62:1412–22.

    Article  PubMed  Google Scholar 

  36. Weber DC, Schneider R, Goitein G, Koch T, Ares C, Geismar JH, et al. Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys. 2012;83:865–71.

    Article  PubMed  Google Scholar 

  37. Jenkinson MD, Weber DC, Haylock BJ, Mallucci CL, Zakaria R, Javadpour M. Radiotherapy versus observation following surgical resection of atypical meningioma (the ROAM trial). Neuro-Oncology. 2014;16:1560–1.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Jenkinson MD, Javadpour M, Haylock BJ, Young B, Gillard H, Vinten J, et al. The ROAM/EORTC-1308 trial: radiation versus observation following surgical resection of atypical meningioma: study protocol for a randomised controlled trial. Trials. 2015;16:519.

    Article  PubMed  PubMed Central  Google Scholar 

  39. • Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383–91. The article is a consensus review of treatment modalities in skull base meningiomas summarizing all relevant modern treatment options.

    Article  PubMed  Google Scholar 

  40. McDonald MW, Plankenhorn DA, McMullen KP, Henderson MA, Dropcho EJ, Shah MV, et al. Proton therapy for atypical meningiomas. J Neuro-Oncol. 2015;123:123–8.

    Article  CAS  Google Scholar 

  41. Boskos C, Feuvret L, Noel G, Habrand JL, Pommier P, Alapetite C, et al. Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys. 2009;75:399–406.

    Article  PubMed  Google Scholar 

  42. Linskey ME. Stereotactic radiosurgery versus stereotactic radiotherapy for patients with vestibular schwannoma: a Leksell Gamma Knife Society 2000 debate. J Neurosurg. 2000;93 Suppl 3:90–5.

    PubMed  Google Scholar 

  43. Meijer OW, Vandertop WP, Baayen JC, Slotman BJ. Single-fraction vs. fractionated linac-based stereotactic radiosurgery for vestibular schwannoma: a single-institution study. Int J Radiat Oncol Biol Phys. 2003;56:1390–6.

    Article  CAS  PubMed  Google Scholar 

  44. Pollock BE, Driscoll CL, Foote RL, Link MJ, Gorman DA, Bauch CD, et al. Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery. 2006;59:77–85.

    Article  PubMed  Google Scholar 

  45. Kondziolka D, Mousavi SH, Kano H, Flickinger JC, Lunsford LD. The newly diagnosed vestibular schwannoma: radiosurgery, resection, or observation? Neurosurg Focus. 2012;33:E8.

    Article  PubMed  Google Scholar 

  46. Pollock BE, Link MJ, Foote RL. Failure rate of contemporary low-dose radiosurgical technique for vestibular schwannoma. Clinical article. J Neurosurg. 2013;119(Suppl):840–4.

    PubMed  Google Scholar 

  47. Wagner J, Welzel T, Habermehl D, Debus J, Combs SE. Radiotherapy in patients with vestibular schwannoma and neurofibromatosis type 2: clinical results and review of the literature. Tumori. 2014;100:189–94.

    PubMed  Google Scholar 

  48. Lo WL, Yang KY, Huang YJ, Chen WF, Liao CC, Huang YH. Experience with Novalis stereotactic radiosurgery for vestibular schwannomas. Clin Neurol Neurosurg. 2014;121:30–4.

    Article  PubMed  Google Scholar 

  49. Anderson BM, Khuntia D, Bentzen SM, Geye HM, Hayes LL, Kuo JS, et al. Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. J Neuro-Oncol. 2014;116:187–93.

    Article  Google Scholar 

  50. Combs SE, Engelhard C, Kopp C, Wiedenmann N, Schramm O, Prokic V, et al. Long-term outcome after highly advanced single-dose or fractionated radiotherapy in patients with vestibular schwannomas—pooled results from 3 large German centers. Radiother Oncol. 2015;114:378–83.

    Article  PubMed  Google Scholar 

  51. Kessel KA, Fischer H, Vogel MM, Oechsner M, Bier H, Meyer B, Combs SE. Erratum to: Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma : Hearing preservation and patients' self-reported outcome based on an established questionnaire. Strahlenther Onkol. 2017;193(2):171. doi:10.1007/s00066-016-1087-4.

  52. Kessel KA, Fischer H, Vogel MM, Oechsner M, Bier H, Meyer B, et al. Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma: hearing preservation and patients’ self-reported outcome based on an established questionnaire. Strahlenther Onkol. 2016. doi:10.1007/s00066-016-1070-0.

  53. Vernimmen FJ, Mohamed Z, Slabbert JP, Wilson J. Long-term results of stereotactic proton beam radiotherapy for acoustic neuromas. Radiother Oncol. 2009;90:208–12.

    Article  PubMed  Google Scholar 

  54. Bush DA, McAllister CJ, Loredo LN, Johnson WD, Slater JM, Slater JD. Fractionated proton beam radiotherapy for acoustic neuroma. Neurosurgery. 2002;50:270–3.

    PubMed  Google Scholar 

  55. Zorlu F, Gurkaynak M, Yildiz F, Oge K, Atahan IL. Conventional external radiotherapy in the management of clivus chordomas with overt residual disease. Neurol Sci. 2000;21:203–7.

    Article  CAS  PubMed  Google Scholar 

  56. Chang SD, Martin DP, Lee E, Adler Jr JR. Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for residual or recurrent cranial base and cervical chordomas. Neurosurg Focus. 2001;10:E5.

    Article  CAS  PubMed  Google Scholar 

  57. Krishnan S, Foote RL, Brown PD, Pollock BE, Link MJ, Garces YI. Radiosurgery for cranial base chordomas and chondrosarcomas. Neurosurgery. 2005;56:777–84.

    Article  PubMed  Google Scholar 

  58. Koga T, Shin M, Saito N. Treatment with high marginal dose is mandatory to achieve long-term control of skull base chordomas and chondrosarcomas by means of stereotactic radiosurgery. J Neuro-Oncol. 2010;98:233–8.

    Article  Google Scholar 

  59. Kano H, Iqbal FO, Sheehan J, Mathieu D, Seymour ZA, Niranjan A, et al. Stereotactic radiosurgery for chordoma: a report from the North American Gamma Knife Consortium. Neurosurgery. 2011;68:379–89.

    Article  PubMed  Google Scholar 

  60. Potluri S, Jefferies SJ, Jena R, Harris F, Burton KE, Prevost AT, et al. Residual postoperative tumour volume predicts outcome after high-dose radiotherapy for chordoma and chondrosarcoma of the skull base and spine. Clin Oncol (R Coll Radiol). 2011;23:199–208.

    Article  CAS  Google Scholar 

  61. Hauptman JS, Barkhoudarian G, Safaee M, Gorgulho A, Tenn S, Agazaryan N, et al. Challenges in linear accelerator radiotherapy for chordomas and chondrosarcomas of the skull base: focus on complications. Int J Radiat Oncol Biol Phys. 2012;83:542–51.

    Article  PubMed  Google Scholar 

  62. Kano H, Lunsford LD. Stereotactic radiosurgery of intracranial chordomas, chondrosarcomas, and glomus tumors. Neurosurg Clin N Am. 2013;24:553–60.

    Article  PubMed  Google Scholar 

  63. Sahgal A, Chan MW, Atenafu EG, Masson-Cote L, Bahl G, Yu E, et al. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes. Neuro-Oncology. 2015;17:889–94.

    Article  CAS  PubMed  Google Scholar 

  64. Fagundes MA, Hug EB, Liebsch NJ, Daly W, Efird J, Munzenrider JE. Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys. 1995;33:579–84.

    Article  CAS  PubMed  Google Scholar 

  65. Noel G, Habrand JL, Jauffret E, de Crevoisier R, Dederke S, Mammar H, et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol. 2003;179:241–8.

    Article  PubMed  Google Scholar 

  66. Noel G, Feuvret L, Calugaru V, Dhermain F, Mammar H, Haie-Meder C, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol. 2005;44:700–8.

    Article  PubMed  Google Scholar 

  67. Grosshans DR, Zhu XR, Melancon A, Allen PK, Poenisch F, Palmer M, et al. Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes. Int J Radiat Oncol Biol Phys. 2014;90:540–6.

    Article  PubMed  Google Scholar 

  68. Pehlivan B, Ares C, Lomax AJ, Stadelmann O, Goitein G, Timmermann B, et al. Temporal lobe toxicity analysis after proton radiation therapy for skull base tumors. Int J Radiat Oncol Biol Phys. 2012;83:1432–40.

    Article  PubMed  Google Scholar 

  69. Schlampp I, Karger CP, Jakel O, Scholz M, Didinger B, Nikoghosyan A, et al. Temporal lobe reactions after radiotherapy with carbon ions: incidence and estimation of the relative biological effectiveness by the local effect model. Int J Radiat Oncol Biol Phys. 2011;80:815–23.

    Article  PubMed  Google Scholar 

  70. Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jakel O, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys. 2007;68:449–57.

    Article  PubMed  Google Scholar 

  71. • Stacchiotti S, Sommer J. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16:e71–83. The present article is a consensus statement on state-of-the-art treatment of skull base chodromas and chondrosarcomas and provides a comprehensive review of treatment modalities and outcomes.

    Article  PubMed  Google Scholar 

  72. McAllister B, Archambeau JO, Nguyen MC, Slater JD, Loredo L, Schulte R, et al. Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities. Int J Radiat Oncol Biol Phys. 1997;39:455–60.

    Article  CAS  PubMed  Google Scholar 

  73. Habrand JL, Schneider R, Alapetite C, Feuvret L, Petras S, Datchary J, et al. Proton therapy in pediatric skull base and cervical canal low-grade bone malignancies. Int J Radiat Oncol Biol Phys. 2008;71:672–5.

    Article  PubMed  Google Scholar 

  74. MacDonald SM, Trofimov A, Safai S, Adams J, Fullerton B, Ebb D, et al. Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. Int J Radiat Oncol Biol Phys. 2011;79:121–9.

    Article  PubMed  Google Scholar 

  75. Combs SE, Kessel KA, Herfarth K, Jensen A, Oertel S, Blattmann C, et al. Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data. Radiat Oncol. 2012;7:170.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Rombi B, DeLaney TF, MacDonald SM, Huang MS, Ebb DH, Liebsch NJ, et al. Proton radiotherapy for pediatric Ewing’s sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys. 2012;82:1142–8.

    Article  PubMed  Google Scholar 

  77. Jimenez RB, Sethi R, Depauw N, Pulsifer MB, Adams J, McBride SM, et al. Proton radiation therapy for pediatric medulloblastoma and supratentorial primitive neuroectodermal tumors: outcomes for very young children treated with upfront chemotherapy. Int J Radiat Oncol Biol Phys. 2013;87:120–6.

    Article  PubMed  Google Scholar 

  78. MacDonald SM, Sethi R, Lavally B, Yeap BY, Marcus KJ, Caruso P, et al. Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro-Oncology. 2013;15:1552–9.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Rombi B, Ares C, Hug EB, Schneider R, Goitein G, Staab A, et al. Spot-scanning proton radiation therapy for pediatric chordoma and chondrosarcoma: clinical outcome of 26 patients treated at Paul Scherrer Institute. Int J Radiat Oncol Biol Phys. 2013;86:578–84.

    Article  PubMed  Google Scholar 

  80. Rieber JG, Kessel KA, Witt O, Behnisch W, Kulozik AE, Debus J, et al. Treatment tolerance of particle therapy in pediatric patients. Acta Oncol. 2015;54:1049–55.

    Article  CAS  PubMed  Google Scholar 

  81. Pulsifer MB, Sethi RV, Kuhlthau KA, MacDonald SM, Tarbell NJ, Yock TI. Early cognitive outcomes following proton radiation in pediatric patients with brain and central nervous system tumors. Int J Radiat Oncol Biol Phys. 2015;93:400–7.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Eaton BR, Esiashvili N, Kim S, Weyman EA, Thornton LT, Mazewski C, et al. Clinical outcomes among children with standard-risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival. Int J Radiat Oncol Biol Phys. 2016;94:133–8.

    Article  PubMed  Google Scholar 

  83. Giantsoudi D, Sethi RV, Yeap BY, Eaton BR, Ebb DH, Caruso PA, et al. Incidence of CNS injury for a cohort of 111 patients treated with proton therapy for medulloblastoma: LET and RBE associations for areas of injury. Int J Radiat Oncol Biol Phys. 2016;95:287–96.

    Article  PubMed  Google Scholar 

  84. Eaton BR, Esiashvili N, Kim S, Patterson B, Weyman EA, Thornton LT, et al. Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro-Oncology. 2016;18:881–7.

    Article  PubMed  Google Scholar 

  85. Kahalley LS, Ris MD, Grosshans DR, Okcu MF, Paulino AC, Chintagumpala M, et al. Comparing intelligence quotient change after treatment with proton versus photon radiation therapy for pediatric brain tumors. J Clin Oncol. 2016;34:1043–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Vern-Gross TZ, Indelicato DJ, Bradley JA, Rotondo RL. Patterns of failure in pediatric rhabdomyosarcoma after proton therapy. Int J Radiat Oncol Biol Phys. 2016;96:1070–7.

    Article  PubMed  Google Scholar 

  87. Ares C, Albertini F, Frei-Welte M, Bolsi A, Grotzer MA, Goitein G, et al. Pencil beam scanning proton therapy for pediatric intracranial ependymoma. J Neuro-Oncology. 2016;128:137–45.

    Article  CAS  Google Scholar 

  88. Weber DC, Ares C, Albertini F, Frei-Welte M, Niggli FK, Schneider R, et al. Pencil beam scanning proton therapy for pediatric parameningeal rhabdomyosarcomas: clinical outcome of patients treated at the Paul Scherrer Institute. Pediatr Blood Cancer. 2016;63:1731–6.

    Article  CAS  PubMed  Google Scholar 

  89. Sethi RV, Giantsoudi D, Raiford M, Malhi I, Niemierko A, Rapalino O, et al. Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses. Int J Radiat Oncol Biol Phys. 2014;88:655–63.

    Article  PubMed  Google Scholar 

  90. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016;122:1483–501.

    Article  PubMed  Google Scholar 

  91. Lievens Y, Pijls-Johannesma M. Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol. 2013;23:134–41.

    Article  PubMed  Google Scholar 

  92. Mailhot VR, Kim J, Hollander A, Hattangadi-Gluth J, Michalski J, Tarbell NJ, et al. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer. 2015;121:1694–702.

    Article  Google Scholar 

  93. Mailhot Vega RB, Kim J, Bussiere M, Hattangadi J, Hollander A, Michalski J, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer. 2013;119:4299–307.

    Article  PubMed  Google Scholar 

  94. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32:3810–6.

    Article  PubMed  PubMed Central  Google Scholar 

  95. • Newhauser WD, Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer. 2011;11:438–48. This article gives insights into calculations regarding reduction of integral dose with protons and potential clinical benefits in terms of side effects with focus on secondary malignancies.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Jones B, Wilson P, Nagano A, Fenwick J, McKenna G. Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma. Br J Radiol. 2012;85:e912–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Technical University of Munich (TUM), Ismaninger Straße 22, 81675, Munich, Germany

    Stephanie E. Combs Prof Dr

  2. Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Ingolstädter Landstraße 1, Neuherberg, Germany

    Stephanie E. Combs Prof Dr

Authors
  1. Stephanie E. Combs Prof Dr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanie E. Combs Prof Dr.

Ethics declarations

Conflict of Interest

Stephanie E. Combs is member of advisory board for BMS.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Combs, S.E. Does Proton Therapy Have a Future in CNS Tumors?. Curr Treat Options Neurol 19, 12 (2017). https://doi.org/10.1007/s11940-017-0447-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-017-0447-4

Keywords

Search

Navigation